514 Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989-1002. 9. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168: 599-604. 10. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign pro- static hyperplasia. J Clin Endocrinol Metab 2006;91:2562-8. 11. Seim A, Hoyo C, Ostbye T, Vatten L. The prevalence and corre- lates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int 2005;96:88-92. 12. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behav- iors and the risk of symptomatic benign prostatic hyperplasia: re- sults from the prostate cancer prevention trial. J Urol 2007; 177:1395-400. 13. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2009;12:160-5. 14. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Compo- nents of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62. 15. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a pop- ulation-based sample of African-American men. Am J Epidemiol 2003;157:906-14. 16. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A. Birth weight, abdominal obesity and the risk of lower uri- nary tract symptoms in a population based study of Swedish men. J Urol 2008;179:1891-5. 17. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem 2009;115:86-96. 18. Kogai MA, Lutov UV, Selyatitskaya VG. Hormonal and bio- chemical parameters of metabolic syndrome in male patients with body weight excess and obesity. Bull Exp Biol Med 2008;146:806-8. 19. Vogeser M, Schwandt P, Haas GM, Broedl UC, Lehrke M, Parhofer KG. BMI and hyperinsulinemia in children. Clin Biochem 2009;42:1427-30. 20. Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 2007;100:658-63. 21. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyper- insulinemia with benign prostate hyperplasia. Prostate 2010;70: 79-89. 22. Escobar EL, Gomes-Marcondes MC, Carvalho HF. Dietary fatty acid quality affects AR and PPARgamma levels and prostate growth. Prostate 2009;69:548-58. 23. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsuline- mia and dyslipidemia in non-diabetic benign prostatic hyper- plasia. Clin Chim Acta 2006;370:89-93. 24. Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwell- ing men. BJU Int 2008;101:313-8. 25. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a pro- Korean J Urol 2011;52:507-516 Abdollah et al spective cohort study of Air Force veterans. Urology 2006;68: 1198-205. 26. Lekili M, Müezzinoğlu T, Uyanik BS, Büyüksu C. Serum lipid lev- els in benign prostatic hyperplasia. World J Urol 2006;24:210-3. 27. Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, Talamini R, et al. History of weight and obesity through life and risk of be- nign prostatic hyperplasia. Int J Obes (Lond) 2005;29:798-803. 28. Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000;21:58-64. 29. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association be- tween markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005;29: 310-6. 30. Vikram A, Tripathi DN, Ramarao P, Jena GB. Intervention of D-glucose ameliorates the toxicity of streptozotocin in accessory sex organs of rat. Toxicol Appl Pharmacol 2008;226:84-93. 31. Ikeda K, Wada Y, Foster HE Jr, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol 2000;164:180-5. 32. Kupelian V, Mcvary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the meta- bolic syndrome: results from the Boston Area Community Health Survey. J Urol 2009;182:616-24. 33. Seitter WR, Barrett-Connor E. Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study. Am J Epidemiol 1992;135:500-3. 34. Meigs JB, Mohr B, Barry MJ, Collins MM, Mckinlay JB. Risk fac- tors for clinical benign prostatic hyperplasia in a commun- ity-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44. 35. Hong GS, Shim BS, Chung WS, Yoon H. Correlation between met- abolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: a single institu- tional study. Korean J Urol 2010;51:631-5. 36. Landsberg L. Diet, obesity and hypertension: an hypothesis in- volving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90. 37. McVary K. Lower urinary tract symptoms and sexual dysfunc- tion: epidemiology and pathophysiology. BJU Int 2006;2:23-8. 38. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and pro- static growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203. 39. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994;51:99-107. 40. Mcvary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174: 1327-433. 41. Roehrborn CG, McConnell JD, Kusek J, et al. Impact of baseline PSA and TRUS volume on longitudinal changes in IPSS and max- imum flow rate in MTOPS [Abstract 910]. J Urol 2004;171:241. 42. Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, et al. Mechanisms of prostate atrophy after glandular botulinum neu- rotoxin type a injection: an experimental study in the rat. Eur Urol 2009;56:134-40. 43. Matityahou A, Rosenzweig N, Golomb E. Rapid proliferation of prostatic epithelial cells in spontaneously hypertensive rats: a